Targeting NR1D1 in organ injury: challenges and prospects

IF 16.7 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Military Medical Research Pub Date : 2023-12-11 DOI:10.1186/s40779-023-00495-3

Zi-Yin Zhang-sun, Xue-Zeng Xu, Germaine Escames, Wang-Rui Lei, Lin Zhao, Ya-Zhe Zhou, Ye Tian, Ya-Nan Ren, Darío Acuña-Castroviejo, Yang Yang

{"title":"Targeting NR1D1 in organ injury: challenges and prospects","authors":"Zi-Yin Zhang-sun, Xue-Zeng Xu, Germaine Escames, Wang-Rui Lei, Lin Zhao, Ya-Zhe Zhou, Ye Tian, Ya-Nan Ren, Darío Acuña-Castroviejo, Yang Yang","doi":"10.1186/s40779-023-00495-3","DOIUrl":null,"url":null,"abstract":"Nuclear receptor subfamily 1, group D, member 1 (NR1D1, also known as REV-ERBα) belongs to the nuclear receptor (NR) family, and is a heme-binding component of the circadian clock that consolidates circadian oscillators. In addition to repressing the transcription of multiple clock genes associated with circadian rhythms, NR1D1 has a wide range of downstream target genes that are intimately involved in many physiopathological processes, including autophagy, immunity, inflammation, metabolism and aging in multiple organs. This review focuses on the pivotal role of NR1D1 as a key transcription factor in the gene regulatory network, with particular emphasis on the milestones of the latest discoveries of NR1D1 ligands. NR1D1 is considered as a promising drug target for treating diverse diseases and may contribute to research on innovative biomarkers and therapeutic targets for organ injury-related diseases. Further research on NR1D1 ligands in prospective human trials may pave the way for their clinical application in many organ injury-related disorders.","PeriodicalId":18581,"journal":{"name":"Military Medical Research","volume":"29 1","pages":""},"PeriodicalIF":16.7000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Military Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40779-023-00495-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Nuclear receptor subfamily 1, group D, member 1 (NR1D1, also known as REV-ERBα) belongs to the nuclear receptor (NR) family, and is a heme-binding component of the circadian clock that consolidates circadian oscillators. In addition to repressing the transcription of multiple clock genes associated with circadian rhythms, NR1D1 has a wide range of downstream target genes that are intimately involved in many physiopathological processes, including autophagy, immunity, inflammation, metabolism and aging in multiple organs. This review focuses on the pivotal role of NR1D1 as a key transcription factor in the gene regulatory network, with particular emphasis on the milestones of the latest discoveries of NR1D1 ligands. NR1D1 is considered as a promising drug target for treating diverse diseases and may contribute to research on innovative biomarkers and therapeutic targets for organ injury-related diseases. Further research on NR1D1 ligands in prospective human trials may pave the way for their clinical application in many organ injury-related disorders.

查看原文本刊更多论文

在器官损伤中靶向 NR1D1：挑战与前景

核受体亚家族 1，D 组，成员 1（NR1D1，又称 REV-ERBα）属于核受体（NR）家族，是昼夜节律钟的血红素结合成分，能巩固昼夜节律振荡器。除了抑制与昼夜节律相关的多个时钟基因的转录外，NR1D1 还具有广泛的下游靶基因，这些靶基因密切参与许多生理病理过程，包括多个器官的自噬、免疫、炎症、代谢和衰老。这篇综述重点探讨了 NR1D1 作为关键转录因子在基因调控网络中的关键作用，特别强调了最新发现的 NR1D1 配体的里程碑意义。NR1D1 被认为是治疗各种疾病的有希望的药物靶点，并可能有助于器官损伤相关疾病的创新生物标志物和治疗靶点的研究。在前瞻性人体试验中对 NR1D1 配体的进一步研究可能会为它们在许多器官损伤相关疾病中的临床应用铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Military Medical Research Medicine-General Medicine

CiteScore

38.40

自引率

2.80%

发文量

485

审稿时长

8 weeks

期刊介绍： Military Medical Research is an open-access, peer-reviewed journal that aims to share the most up-to-date evidence and innovative discoveries in a wide range of fields, including basic and clinical sciences, translational research, precision medicine, emerging interdisciplinary subjects, and advanced technologies. Our primary focus is on modern military medicine; however, we also encourage submissions from other related areas. This includes, but is not limited to, basic medical research with the potential for translation into practice, as well as clinical research that could impact medical care both in times of warfare and during peacetime military operations.